Our Pipeline: Highlighting the Promising Drugs in Development
GM28K
Treatment resistant depression (TRD)
A novel approach to treating Treatment-Resistant Depression (TRD), aiming to improve lives and reduce dependency. GM28K represents a groundbreaking advancement in addressing TRD, offering new hope for those struggling with this challenging condition.
GRE2811
Treatment Of Alopecia
Targeting Alopecia with groundbreaking pharmaceutical therapy. GRE2811 stands at the forefront of our efforts to address hair loss, offering a new dimension in the treatment landscape for individuals grappling with Alopecia.
GM2813
Gambling Disorder
Innovative solutions for combating Gambling Disorder. GM2813 represents a dedicated initiative to address the complexities of Gambling Disorder, offering a ray of hope for those entangled in the grip of compulsive gambling.
GM2814
Mild Cognitive Impairment (MCI)
Addressing Mild Cognitive Impairment with advanced drug repurposing strategies. GM2814 symbolizes our commitment to enhancing cognitive health and function. By employing cutting-edge drug repurposing techniques,
Our Innovative Research Pipeline
Our innovative research pipeline underscores our dedication to pioneering pharmaceutical solutions that make a difference in the lives of individuals facing various challenges. Through these promising drug developments, we aim to contribute to a healthier, more resilient future.
